Adicet Bio to Present at Upcoming Investor Conferences

Rhea-AI Summary

Adicet Bio, Inc. (Nasdaq: ACET) will participate in two significant investor conferences in June 2022. The first event is the Truist Securities Cell Therapy Symposium on June 28, where CEO Chen Schor will discuss key innovations in oncology at 11:30 A.M. ET. The second event is the Stifel 2022 Virtual Cell Therapy Summit from June 29-30, featuring a panel on new cell types on June 29 at 1:00 P.M. ET. Adicet focuses on allogeneic gamma delta T cell therapies for cancer, enhancing tumor targeting and immune response.

REDWOOD CITY, Calif. & BOSTON--(BUSINESS WIRE)-- Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in June.

Details of the events are as follows:

Truist Securities Cell Therapy Symposium, Symposia-cel, June 28, 2022

• Chen Schor, President & CEO, will participate in a panel discussion titled, “The Next Cells & Mechanisms to Watch in Oncology” on Tuesday, June 28, 2022, at 11:30 A.M. ET.

Stifel 2022 Virtual Cell Therapy Summit, June 29-30, 2022

• Chen Schor, President & CEO, will participate in a panel discussion titled, “Outlining the Potential of New Cell Types and Novel Approaches” on Wednesday, June 29, 2022, at 1:00 P.M. ET.

About Adicet Bio, Inc.

Adicet Bio, Inc. is a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer. Adicet is advancing a pipeline of “off-the-shelf” gamma delta T cells, engineered with CAR and T cell receptor-like targeting moieties to enhance selective tumor targeting, facilitate innate and adaptive anti-tumor immune response, and improve persistence for durable activity in patients. For more information, please visit our website at http://www.adicetbio.com.

View source version on businesswire.com: https://www.businesswire.com/news/home/20220621005986/en/

Adicet Bio., Inc.

Investor and Media Contacts

Anne Bowdidge

abowdidge@adicetbio.com

Janhavi Mohite

Stern Investor Relations, Inc.

212-362-1200

janhavi.mohite@sternir.com

Source: Adicet Bio, Inc.

FAQ

What are the details of Adicet Bio's participation in investor conferences in June 2022?

Adicet Bio, Inc. (Nasdaq: ACET) will participate in the Truist Securities Cell Therapy Symposium on June 28, 2022, at 11:30 A.M. ET, and the Stifel 2022 Virtual Cell Therapy Summit from June 29-30, 2022, with a panel discussion on June 29 at 1:00 P.M. ET.

Who will represent Adicet Bio at the June 2022 investor conferences?

Chen Schor, the President & CEO of Adicet Bio, will represent the company at both events.

What is the focus of Adicet Bio, Inc.?

Adicet Bio, Inc. is focused on discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer.

What is the significance of the conferences for Adicet Bio?

The investor conferences provide Adicet Bio an opportunity to showcase its advancements in cell therapies and engage with investors in the biotech community.